ZBH · 8-K · 20260805PR335108

Revenue Performance and Mix

ZIMMER BIOMET HOLDINGS, INC. · 2026-08-05 · Importance 43 · Surprise 32 · No source text

2025 net sales increased 7.2% to $8,231.5 million from $7,678.6 million in 2024, with Paragon 28 contributing 2.5 percentage points and foreign exchange contributing 0.8 percentage points to growth. U.S. sales rose 7.3% to $4,764.0 million, while International sales increased 7.0% to $3,467.5 million. S.E.T. sales increased 15.2% to $2,150.2 million, including a 10.5 percentage-point contribution from Paragon 28, while Knees and Hips each increased 4.7%. Volume and mix contributed 6.4% to year-over-year sales growth, while global selling prices had a minimal effect.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiverealized+1.0%Paragon 28 is estimated to contribute an additional 1.0 percent to year-over-year net sales growth until it eclipses the one year…
revenuepositiverealizedSegment Net Sales 2025: Americas $5,191.1 million; EMEA $1,799.2 million; Asia Pacific $1,241.2 million; Total $8,231.5 million.
revenuepositiverealizedSegment Net Sales 2025: Americas $5,191.1 million; EMEA $1,799.2 million; Asia Pacific $1,241.2 million; Total $8,231.5 million.
revenuepositiverealizedSegment Net Sales 2025: Americas $5,191.1 million; EMEA $1,799.2 million; Asia Pacific $1,241.2 million; Total $8,231.5 million.
operating_incomepositiverealizedSegment profit 2025: Americas $2,188.4 million; EMEA $583.9 million; Asia Pacific $433.8 million; Total segment profit $3,206.1 million.
operating_incomepositiverealizedSegment profit 2025: Americas $2,188.4 million; EMEA $583.9 million; Asia Pacific $433.8 million; Total segment profit $3,206.1 million.
operating_incomepositiverealizedSegment profit 2025: Americas $2,188.4 million; EMEA $583.9 million; Asia Pacific $433.8 million; Total segment profit $3,206.1 million.